Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maze Therapeutics, Inc. (Nasdaq: MAZE) SEC filings page brings together the company’s public regulatory disclosures, offering a detailed view of how this clinical-stage biopharmaceutical company reports its activities to U.S. regulators. Maze focuses on small molecule precision medicines for kidney and metabolic diseases, and its filings provide context on both its scientific programs and its capital markets activity.
Maze’s filings include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, and financing transactions. For example, Maze has filed 8-Ks to furnish press releases on second and third quarter financial results, to disclose an oversubscribed private placement of common stock and pre-funded warrants, and to document the appointments of a new chief financial officer and a new chairman of the board.
Investors can also review registration statements, such as the company’s Form S-1, which describes Maze’s business, risk factors, and the resale of shares issued in its 2025 private placement. The S-1 outlines Maze’s focus on human genetics, its Compass platform, and its lead programs MZE829 and MZE782, while also confirming its status as an emerging growth company and smaller reporting company.
Through Stock Titan, these filings are updated in near real time from the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Users can quickly understand what a particular 8-K, S-1, or other filing means for the company without reading every page. Where applicable, filings related to equity financings, registration rights, and governance changes are highlighted so investors can track dilution, board composition, and executive appointments.
For MAZE, monitoring SEC filings is especially relevant for understanding clinical development disclosures, financing capacity, and risk factors associated with its kidney and metabolic disease programs. This page serves as a central resource for reviewing those official documents alongside concise AI-generated explanations.
Maze Therapeutics, Inc. (MAZE) reported that Harold Bernstein, President, R&D & Chief Medical Officer, sold 9,705 shares of common stock on September 4, 2026 in a market transaction at a weighted average price of $26.2238 per share. The sale was made under a Rule 10b5-1 trading plan adopted on September 29, 2025, and Bernstein now holds no shares directly after this transaction.
Maze Therapeutics, Inc. (MAZE) has a notice from officer Harold Bernstein under Rule 144 indicating an intention to sell up to 9,705 shares of common stock through Morgan Stanley Smith Barney LLC on or after September 4, 2026, on NASDAQ.
The shares to be sold were acquired as Restricted Stock Units from the issuer on September 1, 2026. Bernstein also reports several common stock sales during the prior three months, including transactions made pursuant to a Rule 10b5-1 trading plan.
Maze Therapeutics, Inc. (MAZE) reported that its General Counsel and Corporate Secretary, Courtney Phillips, sold a total of 3,993 shares of common stock on September 2–3, 2026. The company states these sales were made to satisfy tax withholding obligations arising from the vesting of restricted stock units, and no Rule 10b5-1 trading plan is reported.
Maze Therapeutics, Inc. (MAZE) reports that officer Atul Dandekar, its CSBO, sold 6,434 shares of Common Stock on September 2 and 3, 2026. The company states these sales were made to satisfy tax withholding obligations arising from the vesting of restricted stock units and not as discretionary open-market sales. The shares were sold in multiple transactions at weighted average prices within ranges from $25.743 to $27.40 per share, and no Rule 10b5-1 trading plan is reported.
Maze Therapeutics, Inc. (MAZE) reported that Chief Executive Officer and director Jason V. Coloma sold an aggregate of 22,638 shares of Common Stock on September 2–3, 2026, in open-market or private transactions to satisfy tax withholding obligations incurred upon the vesting of restricted stock units.
The reported weighted average prices were $26.3760 and $27.1211 per share on September 2, 2026, and $26.0133 and $25.7749 per share on September 3, 2026, with individual trades executed within the price ranges described in the footnotes. Coloma is also reported as having indirect ownership of 18,151 shares held by The Coloma 2021 Irrevocable Trust and 223,355 shares held by the Coloma Family Trust, for which he and his spouse serve as co‑trustees.
Maze Therapeutics, Inc. (MAZE) reported that Harold Bernstein, President, R&D & CMO, sold a total of 10,295 shares of common stock on September 2 and 3, 2026. According to the company’s disclosure, all of these shares were sold solely to satisfy tax withholding obligations arising from the vesting of restricted stock units, and no Rule 10b5-1 trading plan is reported.
Maze Therapeutics, Inc. (MAZE) reported that its General Counsel and Corporate Secretary, Courtney Phillips, exercised previously granted restricted stock units on September 1, 2026, receiving 11,000 shares of Common Stock through an RSU vesting event.
The 11,000 RSUs, each representing a contingent right to one share of Common Stock, vested in connection with an award that vests as to one-half of the total award on September 1, 2026 and September 1, 2027, subject to continued service. These RSUs do not expire; they either vest or are cancelled prior to the vesting date.
Maze Therapeutics, Inc. (MAZE) reported that Chief Strategy and Business Officer Atul Dandekar exercised restricted stock units into common stock on September 1, 2026. 12,500 restricted stock units converted into 12,500 shares of common stock at no cash exercise price, increasing his directly held common shares to 38,750. Each restricted stock unit represents a right to receive one share of common stock upon settlement and vests in two equal tranches on September 1, 2026 and September 1, 2027, subject to his continued service, with units either vesting or being cancelled and not expiring.
Maze Therapeutics, Inc. (MAZE) reported that Chief Executive Officer and director Jason V. Coloma had 50,000 restricted stock units settle into 50,000 shares of common stock on September 1, 2026. On the same date, entities for which he and his spouse serve as co‑trustees sold a total of 34,501 shares of common stock at weighted average prices around $26.30 per share under a Rule 10b5-1 trading plan. Following these transactions, the trusts reported holdings of 223,355 and 18,151 shares, and Coloma held 50,000 shares directly from the RSU settlement.
Maze Therapeutics, Inc. (MAZE) reported that President, R&D & CMO Harold Bernstein exercised stock options and restricted stock units and sold shares on September 1, 2026 pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025. He exercised options for 16,141 shares of common stock at an exercise price of $10.42 per share, received 16,141 shares of common stock, and sold those 16,141 shares at a weighted average price of $26.3622 per share in multiple trades between $26.11 and $26.64. He also converted 20,000 restricted stock units into 20,000 shares of common stock and continues to hold 20,000 restricted stock units that vest in two equal installments on September 1, 2026 and September 1, 2027, all reported as directly owned.